Cover Image

Impact of small molecules on β-catenin and E-cadherin expression in HPV16-positive and -negative squamous cell carcinomas

Background: The validation of potential molecular targets in head and neck squamous cell carcinoma (SCC) is mandatory. β-Catenin and E-cadherin are crucial for cancer progression through epithelial-mesenchymal transition. We analyzed the effect of the tyrosine kinase inhibitors nilotinib, dasatinib,...

Full description

Saved in:
Bibliographic Details
Main Authors: Kramer, Benedikt (Author) , Hock, Clemens (Author) , Lammert, Anne (Author) , Walter, Beatrice (Author) , Birk, Richard (Author) , Hörmann, Karl (Author) , Aderhold, Marc Christoph (Author)
Format: Article (Journal)
Language:English
Published: June 2017
In: Anticancer research
Year: 2017, Volume: 37, Issue: 6, Pages: 2845-2852
ISSN:1791-7530
DOI:10.21873/anticanres.11636
Online Access:Verlag, Volltext: http://dx.doi.org/10.21873/anticanres.11636
Verlag, Volltext: http://ar.iiarjournals.org/content/37/6/2845
Get full text
Author Notes:Benedikt Kramer, Clemens Hock, Johannes David Schultz, Anne Lammert, Beatrice Kuhlin, Richard Birk, Karl Hörmann and Christoph Aderhold
Description
Summary:Background: The validation of potential molecular targets in head and neck squamous cell carcinoma (SCC) is mandatory. β-Catenin and E-cadherin are crucial for cancer progression through epithelial-mesenchymal transition. We analyzed the effect of the tyrosine kinase inhibitors nilotinib, dasatinib, erlotinib and gefitinib on β-catenin and E-cadherin expression in SCC with respect to human papillomavirus (HPV) status. Materials and Methods: Expression of β-catenin and E-cadherin in cell lines UMSCC 11A, UMSCC 14C and CERV196 under the influence of tyrosine kinase inhibitors were analyzed by enzyme-linked immunosorbent assay. Results: All agents reduced β-catenin and E-cadherin expression of HPV16-negative cells. Increased E-cadherin expression was observed after treatment with gefitinib and dasatinib in HPV16-positive cells. Conclusion: All substances, nilotinib, dasatinib, erlotinib and gefitinib have a significant impact on β-catenin and E-cadherin expression in both HPV16-positive and HPV16-negative cells in vitro. Alterations of β-catenin and E-cadherin could provide novel insights for future targeted therapies of head and neck SCC.
Item Description:Gesehen am 13.11.2018
Physical Description:Online Resource
ISSN:1791-7530
DOI:10.21873/anticanres.11636

Similar Items